8 completed, 3 terminated, 1 active not recruiting. 12 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 12 | Completed 8, Terminated 3, Active not recruiting 1 |
| Phase 2 | 2 | Completed 1, Terminated 1 |
Follow dinaciclib: new trials by email Literature Review of dinaciclib trials Research Report on dinaciclib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Venetoclax and Dinaciclib (MK7965) in Patients With Relapsed/Refractory Acute Myeloid Leukemia Venetoclax, Dinaciclib - Cancer - Acute Myeloid Leukemia | Phase 1 | Terminated | AbbVie | 48 | 2018-07-23 | 2022-12-30 |
| Phase 1b Trial of Dinaciclib With Pembrolizumab for Advanced Breast Cancer Dinaciclib, Pembrolizumab - Advanced or Metastatic Breast Cancer, Triple Negative Breast Cancer | Phase 1 | Completed | Jo Chien | 32 | 2016-12-28 | 2022-09-21 |
| Study of Pembrolizumab (MK-3475) in Combination With Dinaciclib (MK-7965) in Hematologic Malignancies (MK-3475-155/KEYNOTE-155) pembrolizumab, dinaciclib - rrCLL, rrMM | Phase 1 | Terminated | Merck Sharp & Dohme LLC | 75 | 2016-03-29 | 2021-03-01 |
| Dinaciclib and Akt Inhibitor MK2206 in Treating Patients With Pancreatic Cancer That Cannot Be Removed by Surgery Akt Inhibitor MK2206, Dinaciclib, Laboratory Biomarker Analysis - Pancreatic Adenocarcinoma, Recurrent Pancreatic Carcinoma | Phase 1 | Completed | National Cancer Institute (NCI) | 42 | 2013-01-15 | 2017-08-22 |
| Dinaciclib, Bortezomib, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma Bortezomib, Dexamethasone, Dinaciclib - Recurrent Plasma Cell Myeloma | Phase 1 | Completed | National Cancer Institute (NCI) | 41 | 2012-12-19 | 2018-05-11 |
| A Study of Dinaciclib in Combination With Rituximab in Participants With Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (P07974) Dinaciclib, Rituximab - Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 1 | Completed | Merck Sharp & Dohme LLC | 5 | 2012-10-01 | 2015-02-10 |
| Dinaciclib and Epirubicin Hydrochloride in Treating Patients With Metastatic Triple-Negative Breast Cancer Dinaciclib, Epirubicin Hydrochloride, Laboratory Biomarker Analysis - Estrogen Receptor Negative, HER2/Neu Negative | Phase 1 | Completed | National Cancer Institute (NCI) | 40 | 2012-08-21 | 2018-03-30 |
| Ofatumumab and Dinaciclib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or B-Cell Prolymphocytic Leukemia Dinaciclib, Laboratory Biomarker Analysis, Ofatumumab - Chronic Lymphocytic Leukemia, Prolymphocytic Leukemia | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 36 | 2012-01-01 | 2018-03-15 |
| Veliparib and Dinaciclib in Treating Patients With Advanced Solid Tumors Dinaciclib, Veliparib - Advanced Malignant Solid Neoplasm | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 121 | 2011-11-11 | 2026-08-03 |
| Dinaciclib in Treating Patients With Stage III-IV Melanoma dinaciclib, pharmacological study, laboratory biomarker analysis - Stage IIIB Melanoma, Stage IIIC Melanoma | Phase 1 / Phase 2 | Terminated | National Cancer Institute (NCI) | 12 | 2009-09-01 | 2017-04-04 |
| Phase 1 Every-3-Week Dosing of SCH 727965 in Patients With Advanced Cancer (Study P04630) SCH 727965, Aprepitant, Ondansetron - Solid Tumors, Lymphoma, Non-Hodgkin | Phase 1 | Completed | Merck Sharp & Dohme LLC | 81 | 2006-10-11 | 2017-10-23 |
| Phase 1 Weekly Dosing of SCH 727965 in Patients With Advanced Cancer (Study P04629AM6) SCH 727965 - Solid Tumors, Lymphoma, Non-Hodgkin | Phase 1 | Completed | Merck Sharp & Dohme LLC | 123 | 2006-08-01 | 2015-04-20 |
Multiple Myeloma (3) · Breast Neoplasms (2) · Leukemia, Lymphocytic, Chronic, B-Cell (2) · Lymphoma, Non-Hodgkin (2) · Triple Negative Breast Neoplasms (2) · Breast Neoplasms, Male (1) · Leukemia, B-Cell (1) · Leukemia, Myeloid, Acute (1) · Leukemia, Prolymphocytic (1) · Melanoma (1) · Neoplasms (1) · Pancreatic Neoplasms (1) · Recurrence (1)
National Cancer Institute (NCI) (6) · Merck Sharp & Dohme LLC (4) · AbbVie (1) · Jo Chien (1)
United States (8) · Australia (1) · Canada (1) · Spain (1)
A. Jo Chien, MD (1) · Frank Hodi (1) · Geoffrey I Shapiro (1) · Kerry Rogers, MD (1) · Nilofer Azad (1) · Shaji Kumar (1) · Stacy Moulder (1)
PMID 23053255, PMID 24131779, PMID 25217392, PMID 25931518, PMID 25947565, PMID 28859059, PMID 34972202
P30CA006516 (2), U01CA062490 (2), UM1CA186716 (2), 2017 (1), N01CM00070 (1), N01CM62207 (1), P30CA006973 (1), P30CA015083 (1), P30CA016058 (1), P30CA016672 (1), P50CA140158 (1), R01CA090687 (1), R01CA152228 (1), R01CA167511 (1), R21CA172997 (1)